Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers from clinical datasets.
Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products.
Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair.
It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.
Location: United Kingdom, England, Cambridge
Member count: 11-50
Total raised: $67M
Founded date: 2016
Investors 3
| Date | Name | Website |
| 02.05.2022 | British Patien... | britishpatient... |
| 08.03.2022 | Flerie Invest | flerie.com |
| 18.05.2023 | Cambridge Inno... | cic.vc |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 07.03.2022 | Series B | $67M | - | cic.vc/new... |
Mentions in press and media 34
| Date | Title | Description | Source |
| 12.04.2023 | Microbioti... | Microbiotica announces clinical trial collaboration with MSD to evaluate MB097 in combination with K... | cic.vc/new... |
| 07.11.2022 | Microbioti... | Microbiotica — unlocking the microbiome as a multi-therapeutic modality Microbiotica’s platform make... | cic.vc/new... |
| 09.09.2022 | Bicycle Th... | Bicycle Therapeutics puts Life Sciences in the vanguard as Business of the Year Business Weekly art... | cic.vc/new... |
| 09.09.2022 | Bicycle Th... | Bicycle Therapeutics puts Life Sciences in the vanguard as Business of the Year Business Weekly art... | cic.vc/new... |
| 27.04.2022 | £225m rais... | £225m raised for Cambridge Innovation Capital’s Fund II Cambridge Independent article | By Mike Sci... | cic.vc/new... |
| 05.04.2022 | Microbioti... | Microbiotica Receives Crohn’s & Colitis Foundation Funding to Develop Ulcerative Colitis Therape... | cic.vc/new... |
| 15.03.2022 | Top Europe... | Top European funding rounds Closed in February 2022 Vestbee article | By Konrad Koncerewicz, Head o... | cic.vc/new... |
| 08.03.2022 | CIC participat... | CIC participates in Microbiotica’s £50m Series B financing to advance microbiome-based therapeutics ... | cambridgenetwo... |
| 08.03.2022 | Microbiotica p... | Microbiotica has raised a £50 million Series B led by Sweden's Flerie Invest and Tencent. The UK-bas... | pitchbook.com/... |
| 07.03.2022 | Microbioti... | Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and bioma... | seventure.... |
Show more